Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized – Forbes

By Dr. Matthew Watson

Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized
Forbes
Investors considering a purchase of Puma Biotechnology Puma Biotechnology, Inc. (NYSE: PBYI) shares, but cautious about paying the going market price of $53.61/share, might benefit from considering selling puts among the alternative strategies at their ...

and more »

Source:
http://news.google.com/news/url?sa=t&fd=R&usg=AFQjCNE8wH6oYamtnfJeeqKImWmmETyysg&url=http://www.forbes.com/sites/stockoptionschannel/2013/07/19/commit-to-purchase-puma-biotechnology-at-45-earn-14-8-annualized/



categoriaUncategorized commentoComments Off on Commit To Purchase Puma Biotechnology At $45, Earn 14.8% Annualized – Forbes | dataJuly 21st, 2013

About...

This author published 5852 posts in this site.

Share

FacebookTwitterEmailWindows LiveTechnoratiDeliciousDiggStumbleponMyspaceLikedin

Comments are closed.





Personalized Gene Medicine | Mesenchymal Stem Cells | Stem Cell Treatment for Multiple Sclerosis | Stem Cell Treatments | Board Certified Stem Cell Doctors | Stem Cell Medicine | Personalized Stem Cells Therapy | Stem Cell Therapy TV | Individual Stem Cell Therapy | Stem Cell Therapy Updates | MD Supervised Stem Cell Therapy | IPS Stem Cell Org | IPS Stem Cell Net | Genetic Medicine | Gene Medicine | Longevity Medicine | Immortality Medicine | Nano Medicine | Gene Therapy MD | Individual Gene Therapy | Affordable Stem Cell Therapy | Affordable Stem Cells | Stem Cells Research | Stem Cell Breaking Research

Copyright :: 2024